Impact of Antibiotic Pathway on Community-Acquired Pneumonia Outcomes
Author Information
Author(s): Frei Christopher R, Bell Allison M, Traugott Kristi A, Jaso Terry C, Daniels Kelly R, Mortensen Eric M, Restrepo Marcos I, Oramasionwu Christine U, Ruiz Andres D, Mylchreest William R, Sikirica Vanja, Raut Monika R, Fisher Alan, Schein Jeff R
Primary Institution: The University of Texas at Austin
Hypothesis
Does the use of pathway antibiotics improve survival and reduce hospital costs for patients with community-acquired pneumonia?
Conclusion
Pathway antibiotics were associated with improved patient survival, shorter hospital length of stay, and reduced total hospital costs for patients admitted with community-acquired pneumonia.
Supporting Evidence
- Patients receiving pathway antibiotics had a lower 90-day mortality rate (1.4% vs. 4.5%).
- Mean hospital length of stay was shorter for pathway antibiotic patients (3.9 days vs. 5.0 days).
- Total hospital costs were lower for patients treated with pathway antibiotics ($2,485 vs. $3,281).
Takeaway
Using specific antibiotics for pneumonia can help patients get better faster and cost less to treat.
Methodology
Data were collected from six hospitals for adults diagnosed with pneumonia, comparing those treated with pathway antibiotics to those treated with non-pathway antibiotics.
Potential Biases
Differences in baseline characteristics between groups could influence outcomes.
Limitations
The study was retrospective, which may limit the ability to detect differences due to unmeasured variables.
Participant Demographics
Patients were adults aged 18 and older, with a median age of 58 in the pathway group and 68 in the non-pathway group.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website